Denosumab - A new option in the treatment of osteoporosis

Endokrynologia Polska

Volumn 62, Issue 1, 2011, Pages 79-83

  Franek, Edward ^a,b  

^a CENTRAL CLINICAL HOSPITAL OF THE MINISTRY OF INTERIOR   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Denosumab; Fractures; RANK; RANKL

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; DENOSUMAB; FLUORIDE; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PLACEBO; STRONTIUM;

ADVERSE OUTCOME; AORTA ATHEROSCLEROSIS; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CONCUSSION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRACTURE; FRACTURE HEALING; GLOMERULUS FILTRATION RATE; HIP FRACTURE; HUMAN; KIDNEY FUNCTION; METEORISM; OSTEOPOROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SKIN DISEASE; TREATMENT OUTCOME; VERTEBRA FRACTURE;

EID: 79953823758     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
2. Schett G, Kiechl S, Redlich K et al. Soluble RANKL and risk of nontraumatic fracture. JAMA 2004; 291: 1108-1113. (Pubitemid 38541688)
3. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-495.
4. Min H, Morony S, Sarosi I et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000; 192: 463-474. (Pubitemid 30666247)
5. Helas S, Goettsch C, Schoppet M, et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. Am J Pathol 2009; 175: 473-478. Erratum in: Am J Pathol 2009; 175: 2249.
6. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and oseoprotegerin. Circ Res 2004; 95: 1046-1057. (Pubitemid 39557891)
7. McClung MR, Lewicki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821-831. (Pubitemid 43290920)
8. Lewiecki EM, Miller PD, McClung MR et al. Two-year treatment with denosumab (AMG162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Mineral Res 2007; 22: 1832-1841. (Pubitemid 351229299)
9. Miller PD, Bolognese MA, Lewicki EM et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 93: 2149-2157.
10. Bone HG, Bolognese MA, Yuen CK et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93: 2149-2157. (Pubitemid 351831529)
11. Brown JP, Prince RL, Deal C et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Mineral Res 2009; 24: 153-161.
12. Kendler DL, Roux C, Benhamou CL et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Mineral Res 2010; 25: 72-81.
13. Kendler DL, Bessette L, Hill CD et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporosis Int 2010; 21: 837-846.
14. Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765.
15. Boonen S. J Bone Miner Res 2009; 24(Suppl. 1): abstract A09001311.
16. Jamal SA, Ljungren O, Stehmann-Breen C et al. The effect of denosumab on bone mineral density and fracture by level of renal function. ECTS 2010 Glasgow, UK, abstract PP355 accessed online: http://ects2010.abstractsondemand.com/ showabstract.php?congress=ECTS2010&id=592.10.2010
17. Kiel DP, Grazette L, Siddhanti S et al: Effect of denosumab on 3-year progression of aortic calcification in postmenopausal women with osteoporosis at high risk for cardiovascular events. ECTS 2010 Glasgow, UK, abstract OP36 accessed online: http://ects2010.abstractsondemand.com/showabstract.php? congress=ECTS2010&id=233.10.2010
18. Adami S, Gilchrist N, Lyritis G et al. Effect of denosumab on fracture healing in postmenopausal women with osteoporosis: results from the FREEDOM trial. ECTS 2010 Glasgow, UK, abstract OP24 accessed online: http://ects2010.abstractsondemand.com/showabstract.php?congress=ECTS2010&id= 227.10.2010
19. Lewiecki EM. Denosumab - an emerging treatment for postmenopausal osteoporosis. Expert Opin Biol Ther. 2010; 10: 467-476.